WA WAT Waters Corporation 로딩 중... : 애널리스트의 강세 및 약세 의견

DSA 예약과 북-투-빌 비율이 약 4년 만에 최고 수준(Q3 2022)에 도달하며, 임상 전 수요의 업계 전반 회복이 예상보다 일찍 시작되었음을 시사합니다. — 강한 DSA 수요는 더 넓은 CRO 회복 추세를 나타낼 수 있으며, 경쟁사들도 2026년 하반기에 개선을 볼 수 있습니다.

Management raised every component of FY guidance, citing strong momentum across the portfolio and broad-based end-market recovery, indicating a bullish outlook for the remainder of the year.

Although Evoqua is now part of Xylem, its integration is directly credited for enabling Xylem's growth and margin expansion in industrial markets.

The completed combination with Waters' life sciences business is a structural change for BD, but this mention focuses on the execution being ahead of schedule, not on Waters' own outlook.

Waters Corp, 강력한 생명과학 투자처

TheLAPurchaser는 Udit이 Waters Corporation에 미친 긍정적 영향을 강조하며, 생명과학 섹터의 새로운 모멘텀을 시사합니다.

작성자는 생명과학 섹터가 시장 바닥에 도달했다고 제안합니다.

Agilent's LC instrument replacement cycle is showing 2x peer growth, driven by the Infinity Tree system, signaling a clear share gain over Waters and Thermo Fisher in high-performance liquid chromatography. — A sustained 2x growth differential in a major instrument category would directly pressure Waters' core business and indicate a structural shift in the competitive landscape.

Terry Smith 최대 보유 종목은 Waters Corp; 펀드 포트폴리오 공시.

Management guides to strong industry-leading 5.3% growth for the combined company, with multiple embedded conservative assumptions (e.g., excluding pricing improvements, reshoring, and China stimulus) leaving room for upside.

BD is closing the spin-merger of its life sciences business with Waters, which will create a new combined entity and provide BD with a $4B cash distribution.